VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCBB: PKTX) (http://www.protokinetix.com), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries today announced that the Company has completed the funding requirements for trials to test the effectiveness of their AAGP™ molecule’s anti-inflammatory properties.
